MorphoSys AG / MorphoSys Nominates Karin Eastham and Marc Cluzel as
New Supervisory Board Members . Processed and transmitted by Thomson
Reuters ONE. The issuer is solely responsible for the content of this
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced
today that the Company will nominate Ms. Karin Eastham and Dr. Marc
Cluzel as new members of the Supervisory Board at the Company's Annual
Shareholder Meeting on Thursday, May 31, 2012. Ms. Eastham and Dr.
Cluzel will replace Prof. Dr. Jurgen Drews and Dr. Metin Colpan. Prof.
Drews has been a member of MorphoSys AG's Supervisory Board since
1998, while Dr. Colpan joined in 2004.
"We are delighted to be able to present two highly qualified
candidates for MorphoSys's Supervisory Board," commented Dr. Gerald
Moller, Chairman of the Supervisory Board of MorphoSys AG. "Karin
Eastham and Marc Cluzel both have outstanding track records in our
industry and have contributed to the successful performance of several
companies over the course of their careers."
Karin Eastham is an experienced financial executive who currently
serves as director on the Corporate Boards of Illumina, Inc., Amylin,
Inc., Trius Therapeutics, Inc. and Geron Corporation. From May 2004 to
September 2008, she served as Executive Vice President and Chief
Operating Officer and as a member of the Board of Trustees of the
Burnham Institute for Medical Research, a non-profit corporation
engaged in basic biomedical research. From 1999 to 2004, Ms. Eastham
served as Senior Vice President, Finance, Chief Financial Officer and
Secretary of Diversa Corporation. She previously held similar
positions with CombiChem, Inc. and Cytel Corporation. She also held
several positions, including Vice President, Finance, at Boehringer
Mannheim Diagnostics, from 1976 to 1988. Ms. Eastham received a B.S.
and a M.B.A. from Indiana University and is a Certified Public
Dr. Marc Cluzel, an established innovator and leader in the
pharmaceutical industry, has more than 20 years of extensive knowledge
and experience in Research & Development and product registration in
the USA, Europe and Japan. Dr. Cluzel founded C&F consulting in 2011
and serves also as Executive Vice President of Product Development at
HUYA Bioscience International, LLC. Dr. Cluzel served as global head
of R&D for Sanofi from 2007 to 2011, as Executive Vice President of
Research & Development for Sanofi (Formerly Sanofi-Aventis SA) and
before 2009 as its Senior Vice President of Science and Medical
Affairs. He was also since 2002 chairman and CEO of Sanofi-Synthelabo
R&D France then Sanofi-Aventis R&D France. His career began in
hospital medical care and gradually transitioned to research at Johns
Hopkins University, Baltimore and Guy's Hospital, London. Dr. Cluzel
holds both an MD and a PhD from the University of Montpellier, France.
The full agenda for the Annual General Meeting is available on the
Company's website under
MorphoSys developed HuCAL, the most successful antibody library
technology in the pharmaceutical industry. By successfully applying
this and other patented technologies, MorphoSys has become a leader in
the field of therapeutic antibodies, one of the fastest-growing drug
classes in human healthcare. The company's AbD Serotec unit uses HuCAL
and other antibody technologies to generate superior monoclonal
antibodies for research and diagnostic applications.
Together with its pharmaceutical partners, MorphoSys has built a
therapeutic pipeline of more than 70 human antibody drug candidates
for the treatment of cancer, rheumatoid arthritis, and Alzheimer's
disease, to name just a few. With its ongoing commitment to new
antibody technology and drug development, MorphoSys is focused on
making the healthcare products of tomorrow. MorphoSys is listed on the
Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit
HuCAL@, HuCAL GOLD@, HuCAL PLATINUM@, CysDisplay@, RapMAT@ and arYla@
are registered trademarks of MorphoSys. Ylanthia@ and 100 billion high
potentials are trademarks of MorphoSys AG.
Slonomics@ is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements
concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of
the date of this release and involve risks and uncertainties. Should
actual conditions differ from the Company's assumptions, actual
results and actions may differ from those anticipated. MorphoSys does
not intend to update any of these forward-looking statements as far as
the wording of the relevant press release is concerned.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE